Skip to Main Content

Medicare

Stories here look at drug price hikes, the expanded use of medical AI and a host of Medicare Advantage issues. You’ll also find in-depth coverage from Washington on drug price negotiations, pharmacy benefit managers, budget-cuttings and more.

Latest

Politics Rachel Cohrs Zhang and John Wilkerson

STAT Plus: Harris seeks to tie expanded Medicare drug price negotiation to home care, vision, hearing coverage expansion

Pharmalot Adam Feuerstein

STAT Plus: Pharmalittle: We’re reading about an Italian acquisition, Medicare Advantage market growth, and more

Insurance Tara Bannow and Bob Herman

STAT Plus: Medicare Advantage market expected to grow in 2025, despite big changes from insurers

Business Bob Herman

STAT Plus: UnitedHealth sues Medicare to reverse downgraded star ratings

D.C. Diagnosis Rachel Cohrs Zhang

STAT Plus: Medicare will continue its cautious approach to paying for Alzheimer’s drugs

Politics John Wilkerson and Rachel Cohrs Zhang

STAT Plus: Hassan indicates she’s open to tweaks on site-neutral payment reforms

First Opinion Paul Ginsburg and Steve Lieberman

How the next president should reform Medicare

Health tech Katie Palmer

STAT Plus: As Medicare spending on remote patient monitoring jumps, HHS watchdog warns of fraud, misuse

All Coverage

Politics Mario Aguilar and Rachel Cohrs Zhang

STAT Plus: House panel advances bill to extend Medicare’s telehealth flexibilities, setting up December talks

Health Care Inc. Bob Herman

STAT Plus: How insurers are covering Humira and copycat medicines

advertisement

First Opinion Ge Bai

Health care price regulation is undemocratic

First Opinion Peter J. Neumann, Elliott Crummer, Anna Kaltenboeck, and Sean R. Tunis

Medicare’s new transitional coverage of emerging technologies program doesn’t go far enough

Exclusive Bob Herman

STAT Plus: Centene eliminates brokers’ commissions for Medicare drug plans

Health Care Inc. Bob Herman

Patient volumes have stormed back into hospitals

Politics Sarah Owermohle

STAT Plus: 5 health issues to watch for at the Democratic National Convention

First Opinion Sarah Emond

STAT Plus: What the newly released Medicare prices for 10 drugs do and don’t tell us

Politics Sarah Owermohle and Rachel Cohrs Zhang

STAT Plus: Harris pledges to scrap billions in medical debt with new presidential platform

Politics Rachel Cohrs Zhang

STAT Plus: What do Biden’s drug price comparisons reveal? Not much

The Readout LOUD Allison DeAngelis, Elaine Chen, and Adam Feuerstein

Listen: Drug pricing drops & psychedelics under fire

Politics John Wilkerson and Rachel Cohrs Zhang

STAT Plus: Medicare drug price negotiation didn’t benefit Biden — but it may help Harris

Pharma Rachel Cohrs Zhang

STAT Plus: Medicare announces drug prices for historic first round of negotiations

Pharma Joseph Howlett and Andrea Tamayo

STAT Plus: Arthritis patients resort to an inconvenient Medicare workaround to avoid pricey drugs

D.C. Diagnosis Sarah Owermohle

The politics of mifepristone in the 2024 election

Pharmalot Ed Silverman

STAT Plus: Medicare paid substantially more for J&J’s Stelara when it was covered under Part D than under Part B

Politics Rachel Cohrs Zhang

STAT Plus: Judge rules against Chamber of Commerce in Medicare drug negotiation lawsuit

Health tech Mario Aguilar

STAT Plus: Big Health gets FDA nod for its digital therapy for insomnia

Health tech Lizzy Lawrence

STAT Plus: Medicare finalizes reimbursement rule for breakthrough medical devices

Insurance Bob Herman

STAT Plus: CVS removes top Aetna leader as higher medical costs eat further into profits

A STAT Investigation Casey Ross, Lizzy Lawrence, Bob Herman, and Tara Bannow

STAT Plus: Health Care's Colossus: How UnitedHealth turned a questionable artery-screening program into a gold mine